Extended Data Fig. 2: Longitudinal changes in the FAQ score from baseline to week 78. | Nature Aging

Extended Data Fig. 2: Longitudinal changes in the FAQ score from baseline to week 78.

From: TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease

Extended Data Fig. 2: Longitudinal changes in the FAQ score from baseline to week 78.

Adjusted mean change from baseline (±SE) up to week 78 on FAQ score. A greater positive change indicates worsening of symptoms. Sample sizes for each group at each time point are listed for each panel. Analyses were two-sided at 5% significance level. No adjustments were made for multiple comparisons.

Source data

Back to article page